SCHEMBL2960924

SCHEMBL2960924

CC1(C)OB(c2ccc3oc(C(=O)c4ccccc4)cc3c2)OC1(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.56
RAB9A P51151 4/20 0.56
TSHR P16473 2/20 0.56
MAPK1 P28482 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
HPGD P15428 2/20 0.48
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28339887 0.85 PIM1 (0.51) TSHRMAPK1SMN1; SMN2ALDH1A1HPGD
SCHEMBL17206037 0.80 HIF1A (0.41) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL6225537 0.77 MAOB (0.44) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL29926382 0.77 PRMT5 (0.41) SMN1; SMN2ALDH1A1HPGDFLT3
SCHEMBL23810607 0.77 PRMT5 (0.41) SMN1; SMN2ALDH1A1HPGDFLT3
SCHEMBL24943919 0.77 TAS1R3 (0.49) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL5800648 0.76 P4HB (0.62) NPC1RAB9AALDH1A1HPGDP4HB
SCHEMBL30896588 0.76 L3MBTL1 (0.52) MAPK1SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL4658432 0.76 L3MBTL1 (0.52) MAPK1SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL657637 0.76 NPC1 (0.70) NPC1RAB9ATSHRMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 NPC1 1884/4885RAB9A 1753/4885TSHR 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.